bevacizumab
Interviews and expert commentary tagged “bevacizumab” — the latest oncology research and clinical practice from the Audio Journal of Oncology.
Audio Journal of Oncology Volume 16 Number 11
Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan) Sarah Maxwell and Peter Goodwin report from: American Society of Clinical Oncology
Audio Journal of Oncology Volume 16 Number 10
Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan) Commenting Expert: Michael Untch, HELIOS Klinikum, Berlin In this edition Peter Goo
Audio Journal of Oncology Volume 16 Number 8
Scientific Editors: George Canellos, Pat Price, Gordon McVie, Gianni Bonadonna In this edition: Bevacizumab and Survival in Metastatic Breast Cancer Source: N Engl J Med 357:26 George Canellos, Dana-F
Bevacizumab: New Standard for Non-Small Cell Lung Cancer?
Christian Manegold Nick Thatcher Christian Manegold, Heidelberg University Medical Center, Manheim Nick Thatcher, Christie Hospital, Manchester Is bevacizumab a new standard of care for patients with
Neoadjuvant Trastuzumab: Marked Benefit in HER2-Positive Inflammatory Breast Cancer
Jose Baselga Gordon McVie REFERENCE: ABSTRACT 2030, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007 JOSE BASELGA, Vall d’Hebron University Hospital, Barcelona CO
ASCO Audio Journal of Oncology in Advance -July 1st, 2007 – reporting from: ASCO Annual Meeting, Chicago, June 1-5, 2007
Christian Manegold Roy Herbst More Support for Bevacizumab in Advanced Lung Cancer REFERENCE: Abstract LBA7514, ASCO Annual Meeting Chicago June 1-5, 2007 CHRISTIAN MANEGOLD, Heidelberg University, Ma
Audio Journal of Oncology in Advance – November 1st, 2006
David Cameron Martine Piccart Eric Van Cutsem Jim Cassidy Volker Heinemann Lapatinib Better for Patients with HER2+ Refractory Breast Cancer Pre-treated with Chemotherapy and Trastuzumab REFERENCE: ES